Samsung Bioepis’ ‘Benepali’ & ‘Flixabi’ showing significant sales growths
Biogen, a European seller of Samsung Bioepis’ ‘Benepali’ and ‘Flixabi,’ has announced their performance(4th quarter performance in Europe) on the 25th(local time).
According to the performance, ‘Benepali(Enbrel biosimilar’) and ‘F;oxabi(Remicade biosimilar),’ anti-TNF alpha antibodies developed ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
